Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
New Detailing Guidelines Take Effect on April 1; Q&A on Information Supply on Unapproved Drugs/Indications Issued
The Ministry of Health, Labor and Welfare’s (MHLW) new guidelines on ethical drug detailing activities were implemented on April 1, with a Q&A on the supply of information on unapproved drugs issued by the ministry offering yardsticks for determining whether…
To read the full story
Related Article
- Over 30% of Drug Makers Spot Inappropriate Promotions after Guidelines Enforcement
June 16, 2021
- MHLW to Run Fresh Survey on Drug Makers’ Responses to Promotion Guidelines
January 13, 2021
- “Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
January 28, 2020
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
- Wholesalers Working Out Systems to Comply with Promotion Guidelines, Show Mixed Approaches to External Oversight
October 8, 2019
- New Detailing Guidelines Go into Full Effect on October 1, Making Supervisory Systems Mandatory
October 1, 2019
- Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
April 10, 2019
REGULATORY
- Public Comments Warn Japan’s Drug Pricing System Cannot Reflect Inflation: Chuikyo
February 2, 2026
- Chuikyo Agrees to Apply Originator Optimal-Use Guidelines to Biosimilars
February 2, 2026
- MHLW Panel Sets Safety Rules for Upcoming Pomalyst Generics
February 2, 2026
- Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
- MHLW to Ease Uniform Driving Restrictions on Oral Antiepileptics
January 29, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…